Literature DB >> 20649639

Forearm vasodilator reactivity in homozygous carriers of the 9p21.3 rs1333049 G>C polymorphism.

Stefan Aschauer1, Friedrich Mittermayer, Claudia C Wagner, Wolfgang M Schmidt, Martin Brunner, Helmuth Haslacher, Michael Wolzt, Markus Müller.   

Abstract

AIM: Recently, a novel susceptibility locus for coronary artery disease (CAD) has been identified on chromosome 9p21.3, linked to the single-nucleotide polymorphism (SNP) rs1333049 G>C. However, the physiological mechanism through which this locus confers an increased CAD-risk is still unknown. The aim of the present case-control study was to test whether this chromosome 9p21.3 locus, represented by the rs1333049 variant, is associated with altered vasodilator resistance vessel function in healthy young volunteers. DESIGN AND
RESULTS: A total of 97 healthy male volunteers were screened for homozygous carriers of either the G- or the C-allele, the minor allele in European populations. Forearm blood flow (FBF) reactivity to acetylcholine (ACh) and glycerol trinitrate (GTN) was then studied in 10 C/C-genotype carriers compared with 10 control subjects harbouring the G/G-genotype. FBF responses to ACh and GTN were reduced in subjects homozygous for the C-allele of the rs1333049 SNP (P < 0.05). FBF reactivity to the highest dose of ACh and GTN was 95% and 74% lower when compared with control subjects with the G/G-genotype.
CONCLUSION: Our study revealed a functional impairment in forearm artery vasodilator resistance in carriers of the rs1333049 C/C-genotype, thus providing evidence for a first physiological functional link underlying the genetic association of the 9p21.3 locus with an increased cardiovascular risk.

Entities:  

Mesh:

Year:  2010        PMID: 20649639     DOI: 10.1111/j.1365-2362.2010.02321.x

Source DB:  PubMed          Journal:  Eur J Clin Invest        ISSN: 0014-2972            Impact factor:   4.686


  2 in total

1.  No evidence for association of Chr 9p21 variant rs1333049 with gout in New Zealand case-control sample sets.

Authors:  Angela Hsu; Nicola Dalbeth; Peter Gow; Andrew Harrison; John Highton; Peter B Jones; Lisa K Stamp; Tony R Merriman
Journal:  Rheumatology (Oxford)       Date:  2012-03-06       Impact factor: 7.580

2.  Effect of 9p21.3 (lncRNA and CDKN2A/2B) variant on lipid profile.

Authors:  Baozhu Wei; Yang Liu; Hang Li; Yuanyuan Peng; Zhi Luo
Journal:  Front Cardiovasc Med       Date:  2022-09-07
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.